BCAS1 antibody (AA 542-584) (FITC)

Catalog No. ABIN1391420

Product Details anti-BCAS1 Antibody (FITC)

Target: BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))

Binding Specificity: AA 542-584

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This BCAS1 antibody is conjugated to FITC

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Predicted Reactivity: Human,Mouse,Rat

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human BCAS1

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for BCAS1

Target: BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))

Alternative Name: BCAS1/NABC1 (BCAS1 Products)

Synonyms: AIBC1 antibody, NABC1 antibody, 2210416M21Rik antibody, 9030223A09Rik antibody, AI841227 antibody, Band83 antibody, Pmes-2 antibody, BCAS1 antibody, MGC152145 antibody, breast carcinoma amplified sequence 1 antibody, BCAS1 antibody, Bcas1 antibody

Background:

Synonyms: AIBC 1, AIBC1, Amplied and overexpressed in breast cancer, BCAS 1, BCAS1, BCAS1_HUMAN, Breast carcinoma amplied sequence 1, Breast carcinoma-amplied sequence 1, Novel amplied in breast cancer 1.

Background: NaBC1 is a protein found amplified in most breast carcinoma forms. It is expressed primarily as a cytoplasmic, detergent-stable homodimer that has a tendency to interact with DYNLL1 (PIN) and DYNLL2. Breast tumor lines that exhibit 20q13.2 gene amplification express much higher levels of the protein as compared to the levels found in other breast cancer lines that do not overexpress the NaBC1 mRNA. However, this upregulation does not affect growth rate or anchoring abilities of a cell, indicating the oncogenic properties of NaBC1 differ from that of other oncogenes.